SSRI ads questioned

Meek, Colin
March 2006
CMAJ: Canadian Medical Association Journal;3/14/2006, Vol. 174 Issue 6, p754
Academic Journal
Focuses on the comments of Wayne Goodman, chairman of the U.S. Food and Drug Administration Psychopharmacological Drugs Advisory Committee, on drug monographs and advertisements about the physiological mechanism of selective serotonin reuptake inhibitor (SSRI). Argument of Goodman against the claims of the advertisements; Claims of some pharmaceutical companies on the physiological effect of SSRI; Clinical applications of SSRI.


Related Articles

  • SSRIs: CARDIOVASCULAR BENEFITS? L. S. // Primary Psychiatry;Jun2010, Vol. 17 Issue 6, p19 

    The article discusses the benefit of selective serotonin reuptake inhibitors (SSRIs) for cardiovascular health based on a study by Evangelos Litinas et al. of Loyola University Medical Center in Chicago, Illinois.

  • Serotonin Reuptake Inhibition: An Update on Current Research Strategies. Spinks, D.; Spinks, G. // Current Medicinal Chemistry;Apr2002, Vol. 9 Issue 8, p799 

    Selective Serotonin reuptake inhibitors (SSRIs) have contributed to the major advances in the treatment of depression and other psychiatric diseases. This review summarises current knowledge concerning the SSRI class of drugs and discusses the importance of secondary pharmacology in the...

  • The effect of chronic fluvoxamine on hormonal and psychological responses to buspirone in normal volunteers. Anderson, I. M.; Deakin, J. F. W.; Miller, H. E. J. // Psychopharmacology;1996, Vol. 128 Issue 1, p74 

    We studied the effect of 3 weeks treatment with the selective serotonin reuptake inhibitor (SSRI), fluvoxamine, on hormonal and psychological responses to buspirone, a 5-HT[sub 1A] receptor partial agonist which also binds to dopamine receptors, in normal male volunteers. Eleven subjects...

  • Discriminative stimulus properties of the selective norepinephrine reuptake inhibitor, reboxetine, in rats. Dekeyne, Anne; Gobert, Alain; Iob, Loretta; Cistarelli, Laetitia; Melon, Christophe; Millan, Mark J. // Psychopharmacology;2001, Vol. 158 Issue 2, p213 

    Rationale: Although drug discrimination procedures have proven difficult to apply to antidepressant agents, we recently characterized discriminative stimulus properties of the selective serotonin (5-HT) reuptake inhibitor, citalopram, in rats. However, discriminative stimulus properties of...

  • Opinion: Drug safety: walking the marketing tightrope.  // PharmaWatch: CNS;August 2005, Vol. 4 Issue 8, p10 

    The article presents information on the evaluation of the effects of warnings for the use of antidepressants by the American Medical Association (AMA). The AMA has voted to evaluate the usefulness of black-box warnings on antidepressants and to continue prescription drug advertising. The Food...

  • The discriminative stimulus properties of LY233708, a selective serotonin reuptake inhibitor, in the pigeon. Wolff, M. C.; Leander, J. David // Psychopharmacology;1999, Vol. 146 Issue 3, p275 

    Abstract Rationale: Understanding the contribution of the various serotonin (5-HT) receptor subtypes to the behavioral effects of selective serotonin reuptake inhibitors (SSRIs) may contribute to the discovery of increasingly effective drugs for the treatment of conditions such as depression,...

  • Antidepressants have the central role in the pharmacological treatment of agoraphobia with panic disorder.  // Drugs & Therapy Perspectives;Apr2008, Vol. 24 Issue 4, p13 

    Agoraphobia with panic disorder is an under- recognized and undertreated disorder that significantly compromises everyday activities, work and social functioning. Patients develop avoidance behaviour to particular situations and places that cause them anxiety. Antidepressants are the primary...

  • SSRIs Associated With Low Rate of Birth Defects, Studies Show.  // Neurology Alert;Aug2007, Vol. 25 Issue 12, p1 

    This section offers news briefs on pharmacology. According to two new studies in the "New England Journal of Medicine," SSRI are linked to a low rate of birth defects. A study from the Women's Health Initiative is suggesting that estrogen therapy in younger women may prevent cardiovascular...

  • Does agomelatine block 5-HT2 receptors in humans? Sharpley, Ann; Rawlings, Nancy; Brain, Susannah; McTavish, Sarah; Cowen, Philip // Psychopharmacology;Feb2011, Vol. 213 Issue 2/3, p653 

    No abstract available.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics